highest concentration occurring at about 8:00 a.m. and the lowest at about 8:00 p.m.
Average serum concentrations and diurnal variation in testosterone diminish as men age
40% is sequestered with high affinity to sex hormone-binding globulin (SHBG)
almost 60% is bound with low affinity to albumin
2% as free, unbound hormone
5α-DHT has even greater binding affinity to sex hormone-binding globulin than does testosterone
5α-DHT is only about 5% as abundant in the blood as testosterone and is largely derived from peripheral metabolism of testosterone
Both 5α-reduction and aromatization are irreversible processes
Approximately 90% of an oral dose of testosterone is metabolized before it reaches the systemic circulation
there are three modes of action of testosterone. It may directly act through AR in target tissues where 5α-reductase is not expressed, be converted to 5α-DHT (5–10%) by 5α-reductase before binding to AR, or be aromatized to estrogen (0.2%) and act through the estrogen receptor
5α-DHT is a more potent AR ligand than testosterone
has 2–10-fold higher potency than testosterone in androgen-responsive tissues
estrogen plays a major role in regulating metabolic process,74,75 mood and cognition,76 cardiovascular disease,77,78 sexual function including libido,79 and bone turnover in men
Free testosterone is considered the most “biologically active” form
testosterone is the major androgen that acts in the “DHT-independent” tissues, such as skeletal muscle, where 5α-reductase is not expressed or is expressed at a very low level
bioavailable Testosterone found to be approximately 30% of the total circulating Testosterone. Only 1-3% of that percentage is unbound. The other is bound to albumin.
Just the abstract here, but article discusses the various forms of Testosterone. There is protein bound and inactive at apps 70%. Free or bioavailable is at 2-4% with the remaining loosely bound to albumin.
Studies have shown that the production of nagalase has a mutual relationship with Gc-MAF level and immunosuppression
It has been demonstrated that serum levels of nagalase are good prognosticators of some types of cancer
The nagalase level in serum correlates with tumor burden and it has been shown that Gc-MAF therapy progresses, nagalase activity decreases
It has been shown that Gc-MAF can inhibit the angiogenesis induced by pro-inflammatory prostaglandin E1
The effect of Gc-MAF on chemotaxis or activation of tumoricidal macrophages is likely the main mechanism against angiogenesis.
Administration of Gc-MAF stimulates immune-cell progenitors for extensive mitogenesis, activates macrophages and produces antibodies. “This indicates that Gc-MAF is a powerful adjuvant for immunization.”
Cancer cell lines do not develop into tumor genes in mouse models after Gc-MAF-primed immunization (29-31) and the effect of Gc-MAF has been approved for macrophage stimulation for angiogenesis, proliferation, migration and metastatic inhibition on tumors induced by MCF-7 human breast cancer cell line
The protocol included: "a high dose of second-generation Gc-MAF (0.5 ml) administered twice a week intramuscularly for a total of 21 injections.”
Yamamoto et al. showed that the administration of Gc-MAF to 16 patients with prostate cancer led to improvements in all patients without recurrence
Inui et al. reported that a 74-year-old man diagnosed with prostate cancer with multiple bone metastases was in complete remission nine months after initiation of GcMAF therapy simultaneously with hyper T/NK cell, high-dose vitamin C and alpha lipoic acid therapy
It has also been approved for non-neoplastic diseases such as autism (41), multiple sclerosis (42, 43), chronic fatigue syndrome (CFS) (40), juvenile osteoporosis (44) and systemic lupus erythematous (45).
Gc-MAF has been verified for use in colon, thyroid (38), lung (39), liver, thymus (36), pancreatic (40), bladder and ovarian cancer and tongue squamous carcinoma
Prostate, breast, colon, liver, stomach, lung (including mesothelioma), kidney, bladder, uterus, ovarian, head/neck and brain cancers, fibrosarcomas and melanomas are the types of cancer tested thus far
weekly administration of 100 ng Gc-MAF to cancer at different stages and types showed curative effects at different follow-up times
this treatment has been suggested for non-anemic patients
Studies have shown that weekly administration of 100 ng Gc-MAF to cancer patients had curative effects on a variety of cancers
Because the half-life of the activated macrophages is approximately one week, it must be administered weekly
In vivo weekly intramuscular administration of Gc-MAF (100 ng) for 16-22 weeks was used to treat patients with breast cancer
individuals harboring different VDR genotypes had different responses to Gc-MAF and that some genotypes were more responsive than others
Administration of Gc-MAF for cancer patients exclusively activates macrophages as an important cell in adaptive immunity
Gc-MAF supports humoral immunity by producing, developing and releasing large quantities of antibodies against cancer. Clinical evidence from a human model of breast cancer patients supports this hypothesis
There is also evidence that confirms the tumoricidal role of Gc-MAF via Fc-receptor mediation
It is likely that the best therapeutic responses will be observed when the nutritional and inflammatory aspects are taken together with stimulation of the immune system
it should be noted that no harmful side effects of Gc-MAF treatment have been reported, even when it was successfully administered to autistic children
The natural activation mechanism of macrophages by Gc-MAF is so natural and it should not have any side effects on humans or animal models even in cell culture
Besides the Gc-MAF efficacy on macrophage activity, it can be a potential anti-angiogenic agent (28) and an inhibitor of the migration of cancerous cells in the absence of macrophages (47).
Activating or modifying natural killer cells, dendritic cells, DC, CTL, INF and IL-2 have all been recommended for cancer immunotherapy
It has been reported that nagalase cannot deglycosylate Gc-MAF as it has specificity for Gc globulin alone
inflammation-derived macrophage activation with the participation of B and T lymphocytes is the main mechanism
macrophages highly-activated by the addition of Gc-MAF can show tumoricidal activity
Previous clinical investigations have confirmed the efficacy of Gc-MAF. In addition to activating existing macrophages, Gc-MAF is a potent mitogenic factor that can stimulate the myeloid progenitor cells to increase systemic macrophage cell counts by 40-fold in four days
lower levels of SHBG and serum testosterone were found in more recently born men. Preceding generations of men produced higher testosterone levels than men born in more recent generations.
SHBG decreased in hyperinsulinemic states, such as in metabolic syndrome. Low Testosterone has proven to be the same, though not looked at in this study.
Also, in this study, low SHBG is associated with increased cardiovascular mortality.
A number of age-related changes may be relevant:
altered negative feedback of testosterone and hence less increase in luteinizing hormone (LH) with falling testosterone levels,
increased sex hormone binding globulin (SHBG) and hence relatively reduced free testosterone and the likelihood of an age-related
decline in testosterone receptor sensitivity
In the older male, the picture is complicated
by various aging effects, including altered hypothalamo–pituitary feedback, increased testosterone binding and reduced receptor
sensitivity
The neurophysiological basis of NPT is still disputed, but one plausible explanation is that REM sleep is associated with
a ‘switching off’ of the noradrenergic cells in the locus coeruleus
small study, but complex carbs found to increase Testosterone more than high protein diet. That goes against most marketing. In contrast, cortisol was the opposite.
bioavailable testosterone levels decrease much more with age than does total testosterone or estradiol levels
The decrease in bioavailable testosterone parallels the increase in sex hormone binding globulin with age, a change that accompanies increasing body fat independent of weight change
a graded stepwise decrease in bioavailable testosterone with increasing level of depressed mood
This association was independent of age, weight change, and physical activity, the only three significant confounding covariates of the association between sex hormone levels and BDI scores
At the age of 60, testosterone levels are typically only 40-50% of youthful levels and may be lower
Eurycoma contains a group of small peptides referred to as “eurypeptides” that are known to have effects in improving energy status and sex drive in studies of rodents
The effects of tongkat ali in restoring normal testosterone levels appears to be less due to actually “stimulating” testosterone synthesis, but rather by increasing the release rate of “free” testosterone from its binding hormone, sex-hormone-binding-globulin (SHBG)
The current study found that daily supplementation with tongkat ali root extract (200 mg/day) improves stress hormone profile (lower cortisol; higher testosterone) and certain mood state parameters (lower tension, anger, and confusion)
tongkat ali supplementation (100 mg/day) improved lean body mass, 1-RM strength, and arm circumference to a significantly greater degree compared to a placebo group.
In a recent 12-week trial [46] of Eurycoma longifolia supplementation (300 mg/day), men (30–55 years of age) showed significant improved compared to placebo in the Physical Functioning domain of the SF-36 quality of life survey
sexual libido was increased by 11%
In men with low testosterone levels (average age 51 years), one month of daily supplementation with tongkat ali extract (200 mg/day) resulted in a significant improvement in serum testosterone levels and quality-of-life parameters
rise in cortisol and drop in testosterone is an early signal of “overtraining”
Tongkat Ali, commonly known as long jack, is found to reduce stress and increase Testosterone. Stress is one of the common causes of low T in men. It appears that long Jack functions as an adaptogen.
Approximately 95% to 98% of testosterone is bound to a carrier protein at any given time, leaving just the remaining 2% to 5% as completely unbound and available for tissues to use
most serum laboratories offer a free testosterone level, which is a calculated value based on SHBG levels or determined with equilibrium dialysis
the hormone enters the salivary gland by passive diffusion
Testosterone has a known age-related decline, and total levels typically drop by approximately 1.6% per year beginning for most men in their 30s
As estrogen levels rise, they prompt the body to produce more SHBG, which in turn has a higher binding affinity for testosterone, and drives the unbound fraction of the testosterone pool down even further
When the increase in SHBG is taken into account, the age-related decline in the level of hormone that can be used by the body is closer to 2% to 3% per year.
Stinging nettle (Urtica dioica), an herb commonly used for allergies, can also be employed to bind to SHBG, which leaves more testosterone available to tissues
Leptin, an adipose-derived peptide hormone that regulates appetite and metabolism, has been shown to directly inhibit testosterone production in animal models
tumor necrosis factor alpha (TNF-alpha) and interleukin-1 (IL-1) further inhibit Leydig cell testosterone production
Natural aromatase inhibitors include the bioflavonoids chrysin and luteolin
Zinc deficiency causes an upregulation of the aromatase enzyme
there are several herbs that can work to boost testosterone levels, including longjack (Eurycoma longifolia), horny goat weed (Epimedium grandiflorum), and tribulus (Tribulus terrestris).
the majority of the hormone is bound to carrier proteins including sex hormone binding globulin (SHBG) and albumin